Clinical Trials Logo

Clinical Trial Summary

A pilot trial for assessing early microvascular alterations after aneurysmal subarachnoid hemorrhage using dynamic 18F-FDG PET/CT. The primary endpoint will be the measure of early changes in cerebral glucose uptake reflecting microperfusion.


Clinical Trial Description

We hypothesize that an early irreversible microvascular deterioration following initial bleeding could contribute to DCI occurrence. More precisely, we suspect that DCI areas are somehow overlaps of regions in which microperfusion is precociously altered, shortening circulatory reserves, and territories of secondarily spasmed arteries further lowering blood flow, resulting in ischemia. We aim to explore the potential microvasculature alteration through cerebral glucose perfusion and metabolism assessment using early dynamic 18F-fluorodesoxyglucose Positron Emission Tomography/Computer Tomography (dynamic 18F-FDG PET/CT). If our hypothesis turned out to be valid, we would at the same time be able to determine risk factors for this unpredictable complication and gain remarkable insight into DCI pathophysiology. Thus, the purpose of this trial is to demonstrate, in patients affected by SAH, the correlation between early cerebral glucose uptake defects in 18F-FDG PET/CT and delayed cerebral infarction in magnetic resonance imaging (MRI). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04356599
Study type Interventional
Source University Hospital, Montpellier
Contact
Status Completed
Phase N/A
Start date July 22, 2020
Completion date February 19, 2024

See also
  Status Clinical Trial Phase
Completed NCT01832389 - Goal Directed Therapy After Aneurysmal Subarachnoid Haemorrhage N/A
Terminated NCT05259514 - CytoSorb SAH Trial N/A
Completed NCT01801800 - Cardiac Function in Severe Aneurysmal Subarachnoid Haemorrhage Patients N/A